What is NDC 50242-260?

50242-260 is the product NDC for Phesgo, Pertuzumab 600 mg/10mL + 2 more ingredients injection, solution, listed with the FDA by Genentech, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.

What drug is associated with this NDC?

Phesgo (Pertuzumab, trastuzumab, and hyaluronidase-zzxf).

What is the active ingredient?

Pertuzumab, Trastuzumab, Hyaluronidase (Human recombinant).

Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Phesgo?

1 other product NDC are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Phesgo NDC 50242-260 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)50242-260Labeler and product segments. Claims need a package NDC.

Product NDC at billing width50242-0260Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
50242-260-01	50242026001	1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-01) / 10 mL in 1 VIAL, SINGLE-DOSEMarketed from Jun 29, 2020
50242-260-86	50242026086	1 VIAL, SINGLE-DOSE in 1 CARTON (50242-260-86) / 10 mL in 1 VIAL, SINGLE-DOSEMarketed from May 3, 2021 · Sample package

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Phesgo
Generic name (nonproprietary): pertuzumab, trastuzumab, and hyaluronidase-zzxf
Active ingredients: Pertuzumab — 600 mg/10mLTrastuzumab — 600 mg/10mLHyaluronidase (Human recombinant) — 20000 U/10mL
Dosage form: Injection, Solution
Route: Subcutaneous
Labeler: Genentech, Inc.NDC labeler code 50242
Product type: Prescription drug
Marketing category: BLA — Biologics License ApplicationApplication BLA 761170
Marketing start: Jun 29, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Glycoside Hydrolases (Chemical structure)HER2/Neu/cerbB2 Antagonists (Mechanism)HER2/Neu/cerbB2 Antagonists (Mechanism)
Identifiers: Product ID 50242-260_476f0283-10b7-41f4-ade5-f16f4303e8acSPL ID 476f0283-10b7-41f4-ade5-f16f4303e8ac
Pharmacologic class: Endoglycosidase; HER2/neu Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N450242026001 followed by a unit qualifier and the quantity

Package 50242-0260-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

The FDA listing for this product does not reference a label (SPL) set.

About NDC 50242-260

What is NDC 50242-260?: 50242-260 is the product NDC for Phesgo, Pertuzumab 600 mg/10mL + 2 more ingredients injection, solution, listed with the FDA by Genentech, Inc.. It has 2 package NDCs, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Phesgo (Pertuzumab, trastuzumab, and hyaluronidase-zzxf).
What is the active ingredient?: Pertuzumab, Trastuzumab, Hyaluronidase (Human recombinant).
Who is the labeler?: Genentech, Inc., NDC labeler code 50242. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Phesgo?: 1 other product NDC are listed under this name. See all Phesgo NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Phesgo NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxf	Pertuzumab 1200 mg/15mL + 2 more ingredients	Injection, SolutionSubcutaneous	Genentech, Inc.	50242-245	50242-0245-0150242-0245-86

Other NDCs under BLA 761170

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761170
Product	Strength	Form · route	Labeler	Product NDC
Phesgopertuzumab, trastuzumab, and hyaluronidase-zzxf	Pertuzumab 1200 mg/15mL + 2 more ingredients	Injection, SolutionSubcutaneous	Genentech, Inc.	50242-245